Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

(2015) Matthew Warrender-Sparkes et al.   Multiple Sclerosis Journal

Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis

(2015) N. Pfender et al.   NEUROLOGY

2015 Emerging Science Abstracts

(2015)   NEUROLOGY

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

(2015) L. Kappos et al.   NEUROLOGY

Varicella-Zoster Virus Infections in Patients Treated With Fingolimod

(2015) Ann M. Arvin et al.   JAMA Neurology

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

(2015) Anna He et al.   JAMA Neurology

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

(2015) Matthew Warrender-Sparkes et al.   Multiple Sclerosis Journal

Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

(2014) John Camm et al.   AMERICAN HEART JOURNAL

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study

(2014) Cecilie Jacobsen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis

(2014) M. J. Smith et al.   NEUROLOGY

Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model

(2014) Daniel C. Anthony et al.   NEUROPHARMACOLOGY

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study

(2014) Niklas Bergvall et al.   PLoS One

Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

(2014) Nele Claes et al.   PLoS One

Fingolimod for the treatment of neurological diseases—state of play and future perspectives

(2014) Robert Brunkhorst et al.   Frontiers in Cellular Neuroscience

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis

(2014) Niklas Bergvall et al.   JOURNAL OF MEDICAL ECONOMICS

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

(2014) Bruce Hughes et al.   Multiple Sclerosis and Related Disorders

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

(2014) Edward Fox et al.   Multiple Sclerosis and Related Disorders

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

(2014) John P. DiMarco et al.   Multiple Sclerosis and Related Disorders

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

(2014) Ludwig Kappos et al.   Multiple Sclerosis and Related Disorders

Fingolimod phosphate promotes the neuroprotective effects of microglia

(2013) Hiromi Noda et al.   JOURNAL OF NEUROIMMUNOLOGY

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

(2013) Stefan Braune et al.   JOURNAL OF NEUROLOGY

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

(2013) Ralf Gold et al.   JOURNAL OF NEUROLOGY

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

(2013) G Francis et al.   Multiple Sclerosis Journal

Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis

(2013) Marco A. Zarbin et al.   OPHTHALMOLOGY

Initiating oral fingolimod treatment in patients with multiple sclerosis

(2013) Barry A. Singer   Therapeutic Advances in Neurological Disorders

Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis

(2012) Ernst-Wilhelm Radue   ARCHIVES OF NEUROLOGY

Fingolimod treatment in multiple sclerosis leads to increased macular volume

(2012) R. Nolan et al.   NEUROLOGY

Fingolimod protects cultured cortical neurons against excitotoxic death

(2012) Luisa Di Menna et al.   PHARMACOLOGICAL RESEARCH

Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome

(2012) R. Deogracias et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical Pharmacokinetics of Fingolimod

(2011) Olivier J. David et al.   CLINICAL PHARMACOKINETICS

Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers

(2011) Robert Schmouder et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Engagement of S1P1-degradative mechanisms leads to vascular leak in mice

(2011) Myat Lin Oo et al.   JOURNAL OF CLINICAL INVESTIGATION

Impact of sphingosine 1-phosphate modulation on immune outcomes

(2011) D. D. Pinschewer et al.   NEUROLOGY

Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation

(2011) T. Hla et al.   NEUROLOGY

Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices

(2010) Veronique E. Miron et al.   AMERICAN JOURNAL OF PATHOLOGY

Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients

(2010) Matthias Mehling et al.   ANNALS OF NEUROLOGY

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

(2010) Volker Brinkmann et al.   NATURE REVIEWS DRUG DISCOVERY

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

(2010) N. De Stefano et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

(2010) J. W. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systemic Administration of Sphingosine-1-Phosphate Increases Bronchial Hyperresponsiveness in the Mouse

(2009) Fiorentina Roviezzo et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

(2009) David Marsolais et al.   NATURE REVIEWS DRUG DISCOVERY

Balance of S1P1 and S1P2 signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature

(2008) Jen-Fu Lee et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage

(2008) Carolyn A. Foster et al.   BRAIN PATHOLOGY

S1P1 Receptor Signaling Overrides Retention Mediated by Gαi-Coupled Receptors to Promote T Cell Egress

(2008) Trung H.M. Pham et al.   IMMUNITY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

(2008) M. Mehling et al.   NEUROLOGY

FTY720 modulates human oligodendrocyte progenitor process extension and survival

(2007) Veronique E. Miron et al.   ANNALS OF NEUROLOGY